Cargando…

Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer

Prostate cancer (PCa) is the most commonly diagnosed malignant neoplasm in men in the Western world. Localized low-risk PCa has an excellent prognosis thanks to effective local treatments; however, despite the incorporation of new therapeutic strategies, metastatic PCa remains incurable mainly due t...

Descripción completa

Detalles Bibliográficos
Autores principales: Pardo, Juan C., Ruiz de Porras, Vicenç, Gil, Joan, Font, Albert, Puig-Domingo, Manel, Jordà, Mireia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874497/
https://www.ncbi.nlm.nih.gov/pubmed/35215499
http://dx.doi.org/10.3390/nu14040851
_version_ 1784657702619709440
author Pardo, Juan C.
Ruiz de Porras, Vicenç
Gil, Joan
Font, Albert
Puig-Domingo, Manel
Jordà, Mireia
author_facet Pardo, Juan C.
Ruiz de Porras, Vicenç
Gil, Joan
Font, Albert
Puig-Domingo, Manel
Jordà, Mireia
author_sort Pardo, Juan C.
collection PubMed
description Prostate cancer (PCa) is the most commonly diagnosed malignant neoplasm in men in the Western world. Localized low-risk PCa has an excellent prognosis thanks to effective local treatments; however, despite the incorporation of new therapeutic strategies, metastatic PCa remains incurable mainly due to disease heterogeneity and the development of resistance to therapy. The mechanisms underlying PCa progression and therapy resistance are multiple and include metabolic reprogramming, especially in relation to lipid metabolism, as well as epigenetic remodelling, both of which enable cancer cells to adapt to dynamic changes in the tumour. Interestingly, metabolism and epigenetics are interconnected. Metabolism can regulate epigenetics through the direct influence of metabolites on epigenetic processes, while epigenetics can control metabolism by directly or indirectly regulating the expression of metabolic genes. Moreover, epidemiological studies suggest an association between a high-fat diet, which can alter the availability of metabolites, and PCa progression. Here, we review the alterations of lipid metabolism and epigenetics in PCa, before focusing on the mechanisms that connect them. We also discuss the influence of diet in this scenario. This information may help to identify prognostic and predictive biomarkers as well as targetable vulnerabilities.
format Online
Article
Text
id pubmed-8874497
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88744972022-02-26 Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer Pardo, Juan C. Ruiz de Porras, Vicenç Gil, Joan Font, Albert Puig-Domingo, Manel Jordà, Mireia Nutrients Review Prostate cancer (PCa) is the most commonly diagnosed malignant neoplasm in men in the Western world. Localized low-risk PCa has an excellent prognosis thanks to effective local treatments; however, despite the incorporation of new therapeutic strategies, metastatic PCa remains incurable mainly due to disease heterogeneity and the development of resistance to therapy. The mechanisms underlying PCa progression and therapy resistance are multiple and include metabolic reprogramming, especially in relation to lipid metabolism, as well as epigenetic remodelling, both of which enable cancer cells to adapt to dynamic changes in the tumour. Interestingly, metabolism and epigenetics are interconnected. Metabolism can regulate epigenetics through the direct influence of metabolites on epigenetic processes, while epigenetics can control metabolism by directly or indirectly regulating the expression of metabolic genes. Moreover, epidemiological studies suggest an association between a high-fat diet, which can alter the availability of metabolites, and PCa progression. Here, we review the alterations of lipid metabolism and epigenetics in PCa, before focusing on the mechanisms that connect them. We also discuss the influence of diet in this scenario. This information may help to identify prognostic and predictive biomarkers as well as targetable vulnerabilities. MDPI 2022-02-18 /pmc/articles/PMC8874497/ /pubmed/35215499 http://dx.doi.org/10.3390/nu14040851 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pardo, Juan C.
Ruiz de Porras, Vicenç
Gil, Joan
Font, Albert
Puig-Domingo, Manel
Jordà, Mireia
Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer
title Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer
title_full Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer
title_fullStr Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer
title_full_unstemmed Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer
title_short Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer
title_sort lipid metabolism and epigenetics crosstalk in prostate cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874497/
https://www.ncbi.nlm.nih.gov/pubmed/35215499
http://dx.doi.org/10.3390/nu14040851
work_keys_str_mv AT pardojuanc lipidmetabolismandepigeneticscrosstalkinprostatecancer
AT ruizdeporrasvicenc lipidmetabolismandepigeneticscrosstalkinprostatecancer
AT giljoan lipidmetabolismandepigeneticscrosstalkinprostatecancer
AT fontalbert lipidmetabolismandepigeneticscrosstalkinprostatecancer
AT puigdomingomanel lipidmetabolismandepigeneticscrosstalkinprostatecancer
AT jordamireia lipidmetabolismandepigeneticscrosstalkinprostatecancer